Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avacincaptad pegol - IVERIC bio

Next Previous
X
Search
Drug Profile

Avacincaptad pegol - IVERIC bio

Alternative Names: Anti-C5 aptamer; ARC-1905; Avacincaptad pegol sodium; IZERVAY; Zimura

Latest Information Update: 09 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Archemix Corporation
  • Developer IVERIC bio
  • Class Eye disorder therapies; Oligonucleotides; Polyethylene glycols
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry age-related macular degeneration
  • Phase III Stargardt disease
  • Phase II Polypoidal choroidal vasculopathy; Wet age-related macular degeneration

Most Recent Events

  • 01 Apr 2024 FDA assigns PDUFA action date of 19/11/2024 for Avacincaptad pegol for Age-related macular degeneration (AMD)
  • 01 Apr 2024 US FDA accepts sNDA for Avacincaptad pegol for geographic atrophy (GA) secondary to Dry age-related macular degeneration for review
  • 24 Mar 2024 Phase-III clinical trials in Stargardt disease (Intravitreous), prior to March 2024 (Iveric Bio pipeline, March 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top